With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 6, 2017. It's that time of year, so open wide for the fire hose. STAMPEDE and LATITUDE are phase III trials reporting early data at ASCO 2017. Both are looking at adding abiraterone to ADT upfront for metastatic (STAMPEDE and LATITUDE) and locally advanced (STAMPEDE) prostate CA. Both show significantly improved overall survival and disease control. But remember, abiraterone can cause liver toxicity and blood pressure issues. Next step is to combine abiraterone with docetaxel, which also improves survival in this setting. Stay tuned.